Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs liraglutide or dulaglutide for glycemic control and quality of life in type 2 diabetes
jRCT1011200008Active, not recruiting
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms). Primary endpoint: Change in HbA1c at 24 weeks from baseline. Started Nov 2020; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1011200008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011200008.